摘要
目的:研究芪蓟肾康汤对血管紧张素Ⅱ(AngⅡ)诱导的人肾小球系膜细胞(HMCs)信号传导及转录激活蛋白3(STAT3)、细胞因子信号转导抑制因子3(SOCS3)表达的影响,分析芪蓟肾康汤改善IgA肾病,治疗肾小球硬化的机制。方法:采用AngⅡ诱导培养HMCs,使其增殖并分为6组,包括正常组,模型组,替米沙坦组,芪蓟肾康汤低、中、高剂量组。采用MTT法检测细胞是否增殖,确定造模情况。制备芪蓟肾康汤和替米沙坦含药血清,分别加入各组细胞中,酶联免疫吸附法(ELISA法)检测血清中STAT3蛋白表达情况,实时荧光定量PCR法(qPCR法)检测SOCS3 mRNA表达情况。结果:加入AngⅡ后,模型组HMCs出现增殖,造模成功,而且模型组的STAT3表达明显增高、SOCS3表达明显下降。加入芪蓟肾康汤和替米沙坦含药血清后,STAT3表达显著下降(P<0.01),SOCS3表达显著增加(P<0.01),其中芪蓟肾康汤高剂量组最为显著(P<0.01)。结论:芪蓟肾康汤可能通过抑制STAT3和促进SOCS3的表达,抑制肾小球系膜细胞增殖,减轻炎症刺激,进而改善肾小球硬化,治疗IgA肾病。
Objective:To study the effects of Qiji Shenkang Decoction on angiotensin II(Ang II)-induced signal transducer and activator of transcription 3(STAT3)and suppressor of cytokine signaling 3(SOCS3)in human glomerular thylakoid cells(HMCs),thus to analyze the mechanism of Qiji Shenkang Decoction in improving IgA nephropathy and treating glomerulosclerosis.Methods:HMCs were induced to proliferate with Ang II and divided into 6 groups,including the normal group,the model group,the Temsifloxacin group,and the Qiji Shenkang Decoction groups of low-dose,medium-dose and high-dose.The MTT method was used to detect whether the cells proliferated and to determine the modeling status.The western medicinal contained serum and the Chinese medicinal contained serum were prepared respectively and added into the cells of each group.The expression of STAT3 protein was detected by ELISA and the expression of SOCS3 mRNA was detected by q-PCR.Results:After adding Ang II,HMCs in the model group proliferated and were successfully modeled,and the expression of STAT3 was increased and the expression of SOCS3 was decreased in the model group.After adding Chinese medicinal contained serum and the western medicinal contained serum,STAT3 expression significantly decreased(P<0.01),and SOCS3 expression significantly increased(P<0.01),with the most significant increase in the high-dose group of Qiji Shenkang Decoction(P<0.01).Conclusion:Qiji Shenkang Decoction may inhibit STAT3 expression and promote SOCS3 expression,inhibit glomerular thylakoid cell proliferation and reduce inflammatory stimulation to improve glomerulosclerosis and treat IgA nephropathy.
作者
郭建仪
吕静
张春辉
庄晓岩
张忠胜
GUO Jianyi;LYU Jing;ZHANG Chunhui;ZHUANG Xiaoyan;ZHANG Zhongsheng(Liaoning University of Traditional Chinese Medicine,Shenyang 110032,China;Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110032,China)
出处
《中医药学报》
CAS
2022年第8期28-31,共4页
Acta Chinese Medicine and Pharmacology
基金
国家自然科学基金面上项目(81673956)。